V. D. Dodge, E. M. Cox
Dodge & Cox Stock Fund
Dodge & Cox Stock Fund GlaxoSmithKline PLC ADR stake
total: 130
Dodge & Cox Stock Fund GSK trades
- Total transactions:
- 20
- New positions:
- 1
- Added:
- 11
- Reduced:
- 8
- Held since:
- 2019 Q3
- Held for:
- 27 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q1 report, Dodge & Cox Stock Fund holds 42,980,277 GlaxoSmithKline PLC ADR (GSK) shares with a market value of roughly $2.37B accounting for 2.07% of the overall portfolio. To date, the estimated cost basis is nearly $46.23 for "buy" trades and estimated average "sell" price is $52. Dodge & Cox Stock Fund first purchased GSK in 2019 Q3, initially acquiring about 25.55M shares. Since the initial investment in GlaxoSmithKline PLC ADR (GSK), Dodge & Cox Stock Fund has made 19 more transactions.
When did Dodge & Cox Stock Fund buy GlaxoSmithKline PLC ADR (GSK)?
Dodge & Cox Stock Fund first invested in GlaxoSmithKline PLC ADR (GSK) in 2019 Q3 at the reported quarter-end price of $53.35 per share.
What's the cost basis of Dodge & Cox Stock Fund's GSK stake?
The estimated cost basis for GlaxoSmithKline PLC ADR (GSK) stake is around $46.23 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $46.23
- Weighted AVG sell price:
- $52.00
Dodge & Cox Stock Fund's historical trades in GlaxoSmithKline PLC ADR
20 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
2.07%
|
42,980,277
|
$55.19
|
$2,372,081,488
|
-14.99% (-7,576,800)
|
-0.35%
|
|
2025 Q4
|
2.07%
|
50,557,077
|
$49.04
|
$2,479,319,056
|
-13.45% (-7,855,700)
|
-0.32%
|
|
2025 Q1
|
1.99%
|
58,412,777
|
$38.74
|
$2,262,910,981
|
+16.83% (+8,414,700)
|
+0.29%
|
|
2024 Q4
|
1.52%
|
49,998,077
|
$33.82
|
$1,690,934,964
|
-0.10% (-49,900)
|
-0%
|
|
2023 Q3
|
1.96%
|
50,047,977
|
$36.25
|
$1,814,239,166
|
+0.54% (+267,340)
|
+0.01%
|
|
2023 Q2
|
1.91%
|
49,780,637
|
$35.64
|
$1,774,181,903
|
+0.37% (+181,080)
|
+0.01%
|
|
2023 Q1
|
1.98%
|
49,599,557
|
$35.58
|
$1,764,752,238
|
+9.10% (+4,138,800)
|
+0.17%
|
|
2022 Q4
|
1.81%
|
45,460,757
|
$35.14
|
$1,597,491,001
|
+11.63% (+4,735,400)
|
+0.19%
|
|
2022 Q3
|
1.52%
|
40,725,357
|
$29.43
|
$1,198,547,257
|
-0.91% (-375,580.6)
|
-0.01%
|
|
2022 Q2
|
2.62%
|
41,100,937.6
|
$54.41
|
$2,236,404,767
|
-13.26% (-6,282,080)
|
-0.35%
|
|
2021 Q4
|
2.70%
|
$55.12
|
+0.72% (+337,520)
|
|||
|
2021 Q3
|
2.46%
|
$47.76
|
+0.11% (+52,320)
|
|||
|
2021 Q2
|
2.62%
|
$49.78
|
+0.88% (+411,077.6)
|
|||
|
2021 Q1
|
2.56%
|
$44.61
|
+40.46% (+13,417,940)
|
|||
|
2020 Q4
|
2.16%
|
$46.00
|
+42.54% (+9,898,400)
|
|||
|
2020 Q3
|
1.80%
|
$47.05
|
+11.49% (+2,397,840)
|
|||
|
2020 Q2
|
1.78%
|
$50.99
|
-6.79% (-1,520,000)
|
|||
|
2020 Q1
|
2.06%
|
$47.36
|
-9.45% (-2,336,240)
|
|||
|
2019 Q4
|
1.95%
|
$58.74
|
-3.22% (-823,840)
|
|||
|
2019 Q3
|
1.97%
|
$53.35
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.